Atopic Dermatitis (AD)

Immunology·MeSH: Dermatitis, Atopic

Prevalence

7000.0 / 100K

Incidence

800.0 / 100K/yr

13 drugs in development·10 companies·11 clinical trials

Drug Pipeline by Phase

Phase 3(1)

Drug	Company
zl-1503	Zai Lab Ltd (ZLAB)

Phase 2(4)

Drug	Company
evo301	Evommune, Inc. (EVMN)
KT-474/SAR444656	Kymera Therapeutics, Inc. (KYMR)
sim0278	NYMOX PHARMACEUTICAL CORP (NYMXF)
zumilokibart	Apogee Therapeutics, Inc. (APGE)

Phase 1(3)

Drug	Company
apg279	Apogee Therapeutics, Inc. (APGE)
ARQ-234	Arcutis Biotherapeutics, Inc. (ARQT)
gb-7624	Generate Biomedicines Inc. (GENB)

Preclinical(2)

Drug	Company
APG222	Apogee Therapeutics, Inc. (APGE)
EPS-3903	ENANTA PHARMACEUTICALS INC (ENTA)

Unknown(1)

Drug	Company
img-007	ImageneBio, Inc. (IMA)

Phase 4(2)

Drug	Company
Onabotulinum Toxin Type A - Phase 1b	Revance Therapeutics, Inc. (RVNC)
Onabotulinum Toxin Type A - Phase 2	Revance Therapeutics, Inc. (RVNC)

BioSniper tracks 13 drugs in development for Atopic Dermatitis (AD) across 10 companies.

There are 11 clinical trials targeting Atopic Dermatitis (AD) tracked by BioSniper.

The estimated prevalence of Atopic Dermatitis (AD) is approximately 7000.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.